Answers are grounded in this paper and cite their sources.
Metallo-β-lactamases (MBLs) are an emerging cause of bacterial resistance to antibiotic treatment. The VIM-2 β-lactamase is the most commonly encountered MBLs in clinical isolates worldwide. Described here are potent and selective small molecule inhibitors of VIM-2 containing the arylsulfonyl-NH-1,2,3-triazole chemotype that potentiate the efficacy of the β-lactam, imipenem, in Escherichia coli .
No takes yet. Share an insight, caveat, or question.
Weide et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: